Bristol Myers Squibb (CELG-RI) Net Income (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Net Income of $3.3 billion for Q2 2026, up 152.55% year-over-year from $1.3 billion in Q2 2025, and up 23.78% quarter-over-quarter from $2.7 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Net Income (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Net Income for 18 consecutive years, with $3.3 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income rose 152.55% year-over-year to $3.3 billion; the TTM figure through Jun 2026 stood at $9.3 billion (up 83.1% YoY), while the FY2025 annual figure was $7.1 billion, up 178.99% from the prior year.
- Net Income grew to $3.3 billion in Q2 2026 per CELG-RI's latest filing, from $2.7 billion in the prior quarter.
- Across five years, Net Income topped out at $3.3 billion in Q2 2026 and bottomed at -$11.9 billion in Q1 2024.
- Historically, Net Income has averaged $1.0 billion across 5 years, with a median of $1.7 billion in 2023.
- Annual changes were most pronounced in 2024 — Net Income sank 625.28% — and 2025, when it soared 1328.95%.
- Bristol Myers Squibb's Net Income stood at $2.0 billion in 2022, then declined by 12.99% to $1.8 billion in 2023, then slumped by 95.69% to $76.0 million in 2024, then jumped by 1328.95% to $1.1 billion in 2025, then surged by 205.34% to $3.3 billion in 2026.
- Business Quant data shows CELG-RI's Net Income at $3.3 billion in Q2 2026, $2.7 billion in Q1 2026, and $1.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -238.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 3.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.32 Bn |
| Mar 31, 2026 | 2.68 Bn |
| Dec 31, 2025 | 1.09 Bn |
| Sep 30, 2025 | 2.20 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Mar 31, 2025 | 2.46 Bn |
| Dec 31, 2024 | 76.00 Mn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.68 Bn |
| Mar 31, 2024 | -11.91 Bn |
| Dec 31, 2023 | 1.76 Bn |
| Sep 30, 2023 | 1.93 Bn |
| Jun 30, 2023 | 2.08 Bn |
| Mar 31, 2023 | 2.27 Bn |
| Dec 31, 2022 | 2.03 Bn |
| Sep 30, 2022 | 1.61 Bn |
| Jun 30, 2022 | 1.43 Bn |
| Mar 31, 2022 | 1.28 Bn |
| Dec 31, 2021 | 2.37 Bn |
| Sep 30, 2021 | 1.55 Bn |